0001727255 2026-01-01 2026-06-30 0001727255 2026-08-14 0001727255 2026-06-30 0001727255 2025-12-31 0001727255 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001727255 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001727255 us-gaap:SeriesBPreferredStockMember 2026-06-30 0001727255 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001727255 2026-04-01 2026-06-30 0001727255 2025-04-01 2025-06-30 0001727255 2025-01-01 2025-06-30 0001727255 us-gaap:PreferredStockMember 2024-12-31 0001727255 us-gaap:CommonStockMember 2024-12-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001727255 us-gaap:RetainedEarningsMember 2024-12-31 0001727255 2024-12-31 0001727255 us-gaap:PreferredStockMember 2025-03-31 0001727255 us-gaap:CommonStockMember 2025-03-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001727255 us-gaap:RetainedEarningsMember 2025-03-31 0001727255 2025-03-31 0001727255 us-gaap:PreferredStockMember 2025-12-31 0001727255 us-gaap:CommonStockMember 2025-12-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001727255 us-gaap:RetainedEarningsMember 2025-12-31 0001727255 us-gaap:PreferredStockMember 2026-03-31 0001727255 us-gaap:CommonStockMember 2026-03-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001727255 us-gaap:RetainedEarningsMember 2026-03-31 0001727255 2026-03-31 0001727255 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001727255 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001727255 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001727255 2025-01-01 2025-03-31 0001727255 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001727255 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001727255 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001727255 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001727255 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001727255 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001727255 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001727255 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001727255 2026-01-01 2026-03-31 0001727255 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001727255 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001727255 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001727255 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001727255 us-gaap:PreferredStockMember 2025-06-30 0001727255 us-gaap:CommonStockMember 2025-06-30 0001727255 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001727255 us-gaap:RetainedEarningsMember 2025-06-30 0001727255 2025-06-30 0001727255 us-gaap:PreferredStockMember 2026-06-30 0001727255 us-gaap:CommonStockMember 2026-06-30 0001727255 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001727255 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001727255 us-gaap:RetainedEarningsMember 2026-06-30 0001727255 COBA:SeriesBConvertiblePreferredStockMember 2026-01-01 2026-06-30 0001727255 COBA:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-06-30 0001727255 us-gaap:RestrictedStockMember 2026-01-01 2026-06-30 0001727255 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0001727255 COBA:ExerciseOfStockOptionsMember 2026-01-01 2026-06-30 0001727255 COBA:ExerciseOfStockOptionsMember 2025-01-01 2025-06-30 0001727255 srt:MinimumMember 2026-06-30 0001727255 srt:MaximumMember 2026-06-30 0001727255 srt:MinimumMember us-gaap:LandBuildingsAndImprovementsMember 2026-06-30 0001727255 srt:MaximumMember us-gaap:LandBuildingsAndImprovementsMember 2026-06-30 0001727255 COBA:BaltrumMiningConcessionsMember 2025-09-30 0001727255 COBA:Tranche1Member 2026-06-30 0001727255 COBA:Tranche2Member 2026-06-30 0001727255 COBA:Tranche1Member 2025-06-30 0001727255 COBA:Tranche2Member 2025-06-30 0001727255 COBA:ExploitationLevelMember 2026-05-12 0001727255 COBA:ExplorationLevelMiningConcessionsMember 2026-05-12 0001727255 COBA:TermSheetOptionAgreementMember 2026-05-11 2026-05-12 0001727255 COBA:TermSheetOptionAgreementMember 2026-05-12 0001727255 COBA:TermSheetOptionAgreementMember 2026-06-30 0001727255 COBA:SeriesBConvertiblePreferredStockMember 2024-12-26 0001727255 COBA:SeriesBConvertiblePreferredStockMember 2025-12-31 0001727255 COBA:SeriesBConvertiblePreferredIntoCommonStockMember COBA:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001727255 COBA:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001727255 COBA:SeriesBConvertiblePreferredStockMember COBA:CashReceivedMember 2025-01-01 2025-12-31 0001727255 COBA:SeriesBConvertiblePreferredStockMember COBA:SubscriptionsReceivableMember 2025-01-01 2025-12-31 0001727255 us-gaap:PreferredStockMember 2026-06-30 0001727255 COBA:CobaltChileSpaMember 2025-01-01 2025-12-31 0001727255 COBA:MadesalSpAAndGlenoreMember 2025-01-01 2025-12-31 0001727255 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001727255 COBA:GlencoreLtdMember us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001727255 COBA:MadelsalSpaMember us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001727255 COBA:EquityIncentivePlan2022Member 2022-04-26 0001727255 COBA:EquityIncentivePlan2022Member 2026-06-30 0001727255 COBA:OfficersManagersAdvisorsAndDirectorsMember 2022-05-23 2022-05-24 0001727255 COBA:AdvisorMember 2022-05-30 2022-06-01 0001727255 srt:OfficerMember 2022-07-14 2022-07-15 0001727255 COBA:OfficerAndDirectorMember 2022-07-27 2022-07-28 0001727255 COBA:EquityIncentivePlan2023Member 2023-06-29 0001727255 COBA:EquityIncentivePlan2023Member 2026-06-30 0001727255 COBA:OfficersManagementAndDirectorsMember 2023-06-28 2023-07-01 0001727255 COBA:DirectorsMember 2023-07-06 2023-07-07 0001727255 COBA:AdvisoryBoardMember 2024-01-24 2024-01-25 0001727255 COBA:AdvisoryBoardMember 2024-02-12 2024-02-13 0001727255 COBA:OfficersDirectorsAndAdvisoryBoardMember 2025-01-16 2025-01-17 0001727255 COBA:OfficersDirectorsAndAdvisoryBoardMember COBA:Vesting125GrantedSharesMember 2025-01-16 2025-01-17 0001727255 COBA:OfficersDirectorsAndAdvisoryBoardMember 2026-01-01 2026-06-30 0001727255 COBA:OfficersDirectorsAndAdvisoryBoardMember COBA:Vesting25GrantedSharesMember 2025-01-16 2025-01-17 0001727255 COBA:AdvisoryBoardMember 2026-01-01 2026-06-30 0001727255 srt:DirectorMember 2025-07-28 2025-07-29 0001727255 COBA:EquityIncentivePlan2025Member 2025-07-24 0001727255 us-gaap:RestrictedStockUnitsRSUMember COBA:EquityIncentivePlan2025Member 2025-07-25 2026-06-30 0001727255 COBA:ADirectorMember us-gaap:RestrictedStockUnitsRSUMember COBA:EquityIncentivePlan2025Member 2025-08-27 2025-08-28 0001727255 COBA:StockOptionsMember 2026-01-01 2026-06-30 0001727255 COBA:StockOptionsMember 2025-01-01 2025-06-30 0001727255 COBA:StockOptionsMember 2026-04-01 2026-06-30 0001727255 COBA:StockOptionsMember 2025-04-01 2025-06-30 0001727255 COBA:StockOptionsMember 2026-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2025-08-27 2025-08-28 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001727255 srt:MinimumMember 2025-01-01 2025-06-30 0001727255 srt:MaximumMember 2025-01-01 2025-06-30 0001727255 2025-01-01 2025-12-31 0001727255 COBA:OptionsIssuedMay242022Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedMay242022Member 2026-06-30 0001727255 COBA:OptionsIssuedMay242022Member 2025-06-30 0001727255 COBA:OptionsIssuedMay242022Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJune012022Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJune012022Member 2026-06-30 0001727255 COBA:OptionsIssuedJune012022Member 2025-06-30 0001727255 COBA:OptionsIssuedJune012022Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJuly152022Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJuly152022Member 2026-06-30 0001727255 COBA:OptionsIssuedJuly152022Member 2025-06-30 0001727255 COBA:OptionsIssuedJuly152022Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJuly282022Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJuly282022Member 2026-06-30 0001727255 COBA:OptionsIssuedJuly282022Member 2025-06-30 0001727255 COBA:OptionsIssuedJuly282022Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJuly012023Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJuly012023Member 2026-06-30 0001727255 COBA:OptionsIssuedJuly012023Member 2025-06-30 0001727255 COBA:OptionsIssuedJuly012023Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJuly072023Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJuly072023Member 2026-06-30 0001727255 COBA:OptionsIssuedJuly072023Member 2025-06-30 0001727255 COBA:OptionsIssuedJuly072023Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJan252024Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJan252024Member 2026-06-30 0001727255 COBA:OptionsIssuedJan252024Member 2025-06-30 0001727255 COBA:OptionsIssuedJan252024Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedFeb132024Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedFeb132024Member 2026-06-30 0001727255 COBA:OptionsIssuedFeb132024Member 2025-06-30 0001727255 COBA:OptionsIssuedFeb132024Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJan172025Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJan172025Member 2026-06-30 0001727255 COBA:OptionsIssuedJan172025Member 2025-06-30 0001727255 COBA:OptionsIssuedJan172025Member 2025-01-01 2025-06-30 0001727255 COBA:OptionsIssuedJuly292025Member 2026-01-01 2026-06-30 0001727255 COBA:OptionsIssuedJuly292025Member 2026-06-30 0001727255 COBA:OptionsIssuedJuly292025Member 2025-06-30 0001727255 COBA:CORFOMember us-gaap:CashMember 2026-06-30 0001727255 COBA:CORFOMember COBA:InKindContributionsMember 2026-06-30 0001727255 us-gaap:RestrictedStockUnitsRSUMember COBA:AshLazenbyMember 2026-06-30 iso4217:USD shares iso4217:USD shares pure COBA:Integer utr:ha false --12-31 2026 Q2 0001727255

10-Q true 2026-06-30 false 333-268335 CHILEAN COBALT CORP. NV 82-3590294 1199 Lancaster Ave Suite 107 Berwyn PA 19312 484 580-8697 No Yes Non-accelerated Filer true true false false 57972430

3024044

2772082

179438

72231

3203482

2844313

743906

851043

2958

4801389

2847271

75759

35388

53425

15044

129184

50432

129184

50432

0.0001

19848875

0.0001

2900000

0.0001

100000000

57972430

56409930

5797

5641

41797027

39191565

245509

245585

-37376128

-36645952

4672205

2796839

4801389

2847271

18000

19798

40000

19798

398842

295741

754817

635398

-507

-424

-1285

-2596

417349

315963

796102

657792

-417349

-315963

-796102

-657792

32835

15540

5452

33091

12983

-401809

-310511

-730176

-644809

-401809

-310511

-730176

-644809

-0.01

57165425

43502145

56789764

43502145

-401809

-310511

-730176

-644809

3765

-1133

-76

1344

-398044

-311644

-730252

-643465

724420

43502145

4350

33565165

250770

-33382812

437545

1497805

150

673862

674012

2477

55216

-334298

2222225

222

43502145

4350

34294243

253247

-33717110

834952

185560

83483

83502

-1133

55219

-310511

2407785

241

43502145

4350

34432945

252114

-34027621

662029

56409930

5641

39191565

245585

-36645952

2796839

-3841

52809

-328367

56409930

5641

39244374

241744

-36974319

2517440

1562500

156

2499844

2500000

3765

52809

-401809

57972430

5797

41797027

245509

-37376128

4672205

-730176

-644809

105618

110435

110407

21950

24921

-5536

-710044

-561860

505235

-0

1025757 -0

-1530992

830945

2500000

-9870 0

2490130

830945

2868

714

251962

269799

2772082

331309

3024044

601108

36150 0 23310 0

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">1.</td> <td>Organization and Nature of Business</td></tr> </table> The accompanying condensed consolidated financial statements include the accounts of Chilean Cobalt Corp. (the “Company”) (OTCQB: COBA), a Nevada corporation formed on December 4, 2017, and its wholly-owned subsidiary Baltum Minería SpA (“Baltum”), a Chilean Sociedad por Acciones formed on January 3, 2018. The Company is a cobalt and copper, junior mining and exploration company and also has an earn-in option to potentially acquire royalties or concessions in rare earth element mining concessions. Cobalt, a critical mineral for many of the current cathode battery chemistry configuration options in the electric vehicle (“EV”) battery production space, was mined in Chile for 100 years from 1844 thru 1944 and ceased at the end of World War II. Baltum owns exploitation-level mining concessions for 6,377 hectares in the San Juan mining district in northern Chile. On May 12, 2022, the former Parent Company, Genlith, Inc. distributed all of its shares in the Company to its individual shareholders. As of the date of the distribution, Genlith, Inc. no longer held an equity interest in the Company. The Company’s year-end is December 31.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">2.</td> <td>Going Concern</td></tr> </table> The Company has not yet begun to generate revenue as of June 30, 2026, has incurred recurring losses since inception, and expects to continue to incur losses as a result of costs and expenses related to mining exploration and general and administrative expenses. For the three-month and six-month periods ended June 30, 2026, the Company reported a net loss of $401,809 and $730,176, respectively, and had an accumulated deficit of $37,376,128 as of June 30, 2026. The ability of the Company to continue as a going concern over a longer term is dependent on the Company’s ability to raise the financing necessary to complete the exploration and development of cobalt and copper mines and bring mining operations into production and commercialization. Furthermore, the Company’s ability to achieve the milestones required to earn rare earth element mining concession royalties or ownership is also dependent on the Company’s ability to raise the necessary financing. With a cash balance of $3,024,044 as of June 30, 2026, the Company is well positioned to further its strategic objectives, but depending on pace of project development and success in raising capital, may not have sufficient financial resources to continue its operations for the next 12 months, in spite of the existing cash balance and capital raised. Historically the Company has funded its operations with the private placement of equity, debt, and related party loans. However, raising sufficient capital to continue exploration and bring the Company into production and commercialization is dependent on continued discussions with potential off-take partners, debt providers, alternative lenders and investors and is a material uncertainty. There can be no assurance as to the availability or terms upon which such financing or capital might be available. As a result of these factors, there is substantial doubt about the Company’s ability to continue as a going concern.

-401809

-730176

-37376128

3024044

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">3.</td> <td>Summary of Significant Accounting Policies Basis of Presentation</td></tr> </table> The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The financial statements include the consolidated accounts of the Company and Baltum, the Company’s wholly-owned subsidiary. All material intercompany transactions have been eliminated in consolidation. Earnings (Loss) Per Share The weighted-average common shares outstanding for both basic and diluted loss per share for all periods presented was calculated, in accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) 260, Earnings Per Share. To the extent that stock options, warrants and convertible preferred stock are anti-dilutive, they are excluded from the calculation of diluted earnings (loss) per share. As of the three and six-month periods ended June 30, 2026 and 2025, the Company excluded the following shares from the calculation of diluted loss per share because such amounts were anti-dilutive: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl2eKkXLZiK8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies Basis of Presentation (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify">Shares issuable upon conversion of Series B Convertible Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zugjecVobSc4" style="width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zxl9U6rypDX9" style="width: 13%; text-align: right" title="Antidilutive shares">2,407,785</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares issuable upon vesting of Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zRX0IImdGcEj" style="text-align: right" title="Antidilutive shares">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z3sIepAnHALd" style="text-align: right" title="Antidilutive shares">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Shares issuable upon exercise of stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_zh9vyKGqtP8j" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,301,254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_z7UWvoh1KUkj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,431,254</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zsnpMGlbrXqb" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">7,801,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zxF60bltwf04" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">9,839,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Fair Value Measurements The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities, as necessary, and to determine fair value disclosures of financial instruments on a recurring basis. Consistent with ASC Topic 820, Fair Value Measurements (“ASC 820”), assets and liabilities that are required to be recorded at fair value are done so at the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. When measuring fair value, and consistent with the fair value hierarchy in ASC 820, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs consistent with the following fair value hierarchy: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to assess at the measurement date.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Level 3 inputs are unobservable inputs for the asset or liability.</td></tr> </table> For assets and liabilities measured at fair value when there is limited or no observable market data, management applies judgment to estimate fair value and considers factors such as current pricing policy, the economic and competitive environment, the characteristics of the asset or liability, and other factors. The amounts estimated by management cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Inherent limitations in any such fair value calculation technique, including changes in discount rates, estimates of future cash flows, and other underlying assumptions, could significantly affect the results of current or future value. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include but are not limited to the applicability of accrued expenses and volatility used in the determination of stock-based expenses. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. There have been no changes in estimates during the periods presented. Actual results could differ from the Company’s estimates and those differences may be material. Cash Cash amounts consist of cash on hand, bank deposits, and money market accounts. Cash equivalents consist of all liquid debt instruments with original maturities of three months or less. As of June 30, 2026 and December 31, 2025, the Company’s cash balances were $3,024,044 and $2,772,082, respectively, and the Company’s cash equivalents were $-0- and $-0-, respectively. Subscriptions Receivable and Stock Compensation The Company typically reflects subscriptions receivable in stockholders’ equity, unless there is substantial evidence of the intent and ability of the subscriber to pay the amounts in a reasonable amount of time, in which case the subscriptions receivable are instead reflected as an asset on the balance sheet. There were no subscriptions receivable as of June 30, 2026, or December 31, 2025. The Company reflects stock-based compensation at the intrinsic value of the compensation ratably across the periods in which the compensation is earned. When stock is issued for services, the intrinsic value of the stock issued is amortized ratably over the period in which the compensation is earned. In the initial period of amortization, the amortized portion is reflected in preferred or common stock, as applicable, for both shares and the full par value with any residual reflected in additional paid-in capital. The amortization for each subsequent period is reflected entirely in additional paid-in capital. Value Added Tax (“VAT Tax”) The Company’s subsidiary historically has paid significant amounts of VAT Tax to the Chilean government on certain operating purchases. The tax paid can be offset against future VAT Tax due. The Company has not recorded any VAT tax receivables as of June 30, 2026 and December 31, 2025, because the Company’s ability to engage in sales activity necessary to recover VAT taxes paid in on its expenditures is currently indeterminable. Property and Equipment Property, plant, and equipment are stated at cost, less accumulated depreciation. Acquired property, plant and equipment are recognized at their estimated fair value. Capitalized costs may include computers, vehicles, furniture and fixtures, machinery, and equipment, and are depreciated using the straight-line method or unit-of-production method at rates sufficient to depreciate such costs over the shorter of estimated productive lives or the useful life of the individual assets. Useful lives range from 3 to 10 years. Capitalized costs may also include buildings or improvements to land, which if applicable, have useful lives ranging from <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandBuildingsAndImprovementsMember__srt--RangeAxis__srt--MinimumMember_zwSZYfgK9tX3" title="Property and equipment useful lives">20 to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandBuildingsAndImprovementsMember__srt--RangeAxis__srt--MaximumMember_z0xa6nYODdhl" title="Property and equipment useful lives">40 years. Gains and losses are reflected in income or expense upon sale or retirement of assets. Expenditures that extend the useful lives of property, plant and equipment or increase productivity are capitalized. Ordinary repairs and maintenance are expensed as incurred through operating expense. We periodically evaluate whether events or circumstances indicate that the net book value of our property, plant and equipment may not be recoverable. Costs are capitalized when it has been determined an ore body can be economically developed. The development stage begins at new projects when our management and/or board of directors make the decision to bring a mine into commercial production and ends when the production state, or extraction of reserves, begins. The production stage of a mine commences when salable materials, beyond a de minimis amount, are produced. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production and are expensed due to a lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Costs for exploration, evaluation, and pre-development, including drilling costs related to those activities (discussed further below), and repairs and maintenance on capitalized property and equipment are charged to operations as incurred. Drilling, development, and related costs are either classified as exploration, pre-development or secondary development as defined above, and charged to operations as incurred, or capitalized based on the following criteria: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%; text-align: justify">whether the costs are incurred to further define mineralization at and adjacent to existing reserve areas or intended to assist with mine planning within a reserved area;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">whether the drilling or development costs relate to an ore body that has been determined to be commercially mineable, and a decision has been made to put the ore body into commercial production;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">whether, at the time the cost is incurred: (a) the expenditure embodies a probable future benefit that involves a capacity, singly or in combination with other assets, to contribute directly or indirectly to future net cash inflows, (b) we can obtain the benefit and control others’ access to it, and (c) the transaction or event giving risk to our right to or control of the benefit has already occurred.</td></tr> </table> If all of these criteria are met, drilling, development and related costs are capitalized. Drilling and development costs not meeting all of these criteria are expensed as incurred. The following factors are considered in determining whether or not the criteria listed above have been met, and whether capitalization of drilling and development costs is appropriate: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%">Completion of a favorable economic study and mine plan for the ore body targeted;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>authorization of development of the ore body by management and/or the board of directors; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">there is a justifiable expectation, based on applicable laws and regulations, that issuance of permits or resolution of legal issues and/or contractual requirements necessary for us to have the right to or control of the future benefit from the targeted ore body have been met.</td></tr> </table> Drilling and related costs at our properties as of and for the six-months ended June 30, 2026 and June 30, 2025, respectively, and the three-months ended June 30, 2026 and June 30, 2025, respectively, did not meet our criteria for capitalization. When assets are retired or sold, the costs and related allowances for depreciation and amortization are eliminated from the accounts and any resulting gain or loss is reflected in the current period net income (loss). Impairment of Long-lived Assets Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value less cost to sell or dispose, determined based on discounted cash flows. During the six-months and three-months ended June 30, 2026 and 2025, we recorded $-0- and $-0-, respectively, impairment losses in those periods. Baltum presently owns 6,377 hectares of exploitation-level mining concessions in the San Juan mining district, which were recorded as fully impaired and written down to $-<span id="xdx_905_eus-gaap--MineralPropertiesAccumulatedImpairment_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--BaltrumMiningConcessionsMember_zkMJRr0FSvAl" title="Impaired and written down">0- value from approximately $1.9 million in September 2025 in aggregate on the Company’s facilities located in the San Juan mining district of Chile and previously wrote down the remainder, based on the lack of reliability of and availability of independent valuations for these unique assets, as necessary to substantiate their value for financial statement purposes. Under a funding level that allows the Company to focus on exploration, Baltum will continue its exploration activities under these mining concessions toward proving the existence of cobalt and/or copper. Depending on the outcome of the exploration activities, the Company would then consider seeking a preliminary economic assessment, preliminary feasibility study, or definitive feasibility study to validate the expected profitability of constructing a plant to extract the target minerals and process them into saleable products. Environmental Obligations We provide for environmental-related obligations when they are probable and amounts can be reasonably estimated. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Included in our environmental liabilities are costs for the operation, maintenance and monitoring of site remediation plans (“OM&M”). If applicable, such reserves are based on our best estimates for these OM&M plans. Over time we could incur OM&M costs in excess of these reserves. However, we are unable to reasonably estimate an amount in excess of any recorded reserves because we cannot reasonably estimate the period for which such OM&M plans will need to be in place or the future annual cost of such remediation, as conditions at environmental sites change over time. If applicable, such additional OM&M costs could be significant in total but would be incurred over an extended period of years. Environmental remediation charges represent the costs for continuing charges associated with environmental remediation at operating sites from previous years and from products that are no longer manufactured and are currently not applicable. Leases The Company determines if an arrangement is a lease at the inception of the contract. If applicable, our operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities – current, and operating lease liabilities – long term in the condensed consolidated balance sheets. The operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit interest rate, we utilize an estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. In determining the discount rate used in the present value calculation, the Company has elected to apply the portfolio approach for leases provided the leases commenced at or around the same time. This election allows the Company to account for leases at a portfolio level provided that the resulting accounting at this level would not differ materially from the accounting at the individual lease level. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. If leases are applicable, the Company has elected not to separate lease and non-lease components and accounts for each separate lease component and non-lease component associated with that lease component as a single lease component. Operating lease ROU assets include all contractual lease payments and initial direct costs incurred less any lease incentives. Facility leases generally only contain lease expense and non-component items such as taxes and pass-through charges. Additionally, we have elected not to apply the recognition requirements of ASC 842 to leases which have a lease term of less than one year at the commencement date. Mining Concessions Mining concessions are recorded at cost based on the payments required under the contracts. Amortization begins when placed in service after the mining concession is exercised. Mining concessions are amortized over their useful life based on the pattern over which the mining concessions are consumed or otherwise used up. Determination of expected useful lives for amortization calculations is made on a property-by-property or asset-by-asset basis at least annually. At the time an ore body can be economically developed, the basis of the mining concession will be amortized on a units-of-production basis. Pursuant to our policy on the impairment of long-lived assets, if it is determined that a mining concession cannot be economically developed or its innate value has not been independently substantiated, the basis of the mining concession is reduced to its fair value and an impairment loss is recorded to expense in the period in which it is determined to be impaired. Finite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Intangible assets that are not subject to amortization are tested for impairment annually and more frequently if events or changes in circumstances indicate that is more likely than not (meaning more than 50%) that the asset is impaired. The value of the exploitation mining concessions owned by Baltum has yet to be independently substantiated by a valuation or any level of feasibility study. As of June 30, 2026 and December 31, 2025, these mining concessions had a value of $-0- and $-0-, respectively on the Company’s condensed consolidated balance sheet. <p id="xdx_842_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyOngoingBenefitArrangements_zkv7vpj1z4aj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restructuring and Other Charges We continually perform strategic reviews and assess the returns on our businesses. In the event that this results in a plan to restructure the operations of our business, we record an accrual for severance and other exit costs under the provisions of the relevant accounting guidance. Research and Development Research and development costs are expensed as incurred. Foreign Currency The reporting currency of the Company is the U.S. dollar. The functional currency of Baltum, the Company’s wholly-owned subsidiary, is the Chilean Peso. The assets and liabilities of Baltum are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive income or loss within the Company’s condensed consolidated balance sheet. Gains and losses resulting from foreign currency transactions are reflected within the Company’s condensed consolidated statements of operations. Transactions denominated in foreign currency other than our functional currency of the foreign operation are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at each reporting date into the functional currency at the exchange rate at that date. The Company has not utilized foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. There were no material transaction and remeasurement gains for the three and six-months ended June 30, 2025 and 2026, respectively. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company’s wholly owned subsidiary is subject to foreign corporate tax in foreign taxing jurisdictions. We do not provide income taxes on the equity in undistributed earnings of consolidated foreign subsidiaries as it is our intention that such earnings will remain invested in those companies. The Company accounts for income taxes in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Under ASC 740, income tax expense includes federal and state taxes currently payable and deferred taxes arising from temporary differences between income for financial reporting and income tax purposes. In accordance with ASC 740, the Company has evaluated its tax positions. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that has a likelihood of being realized on examination of more than 50 percent. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Under the “more likely than not” threshold guidelines, the Company believes no significant uncertain tax positions exist, either individually or in the aggregate, that would give rise to the non-recognition of an existing tax benefit. The Company’s policy is to account for interest expense and penalties related to unrecognized tax benefits as a component of income tax expense. The Company is currently not under examination with any federal, state, or foreign taxing authorities. In addition, the Company had no material unrecognized tax benefits or accrued interest and penalties as of and for the six-months ended June 30, 2026. Concentration of Credit Risk and of Significant Vendors The Company maintains cash balances at financial institutions in the United States and Chile. The Company holds all cash balances at accredited financial institutions, in amounts that exceed federally insured limits in the United States of America. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Segment Reporting The Company has not yet begun generating revenues from its planned principal operations and operates as a single reportable segment for its cobalt-copper / copper-cobalt projects in Chile. The chief operating decision maker is the Company’s chief executive officer, who assesses the performance based on total expenses, cash flows and progress made in the Company’s ongoing development efforts. All of the Company’s long-lived assets are located in Chile. Recently Issued and Adopted Accounting Pronouncements The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements, including ASC 2023-09, and does not believe that any of these pronouncements will have a material impact on the Company’s current financial position and results of operations.

Earnings (Loss) Per Share The weighted-average common shares outstanding for both basic and diluted loss per share for all periods presented was calculated, in accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting Standards Codification (“ASC”) 260, Earnings Per Share. To the extent that stock options, warrants and convertible preferred stock are anti-dilutive, they are excluded from the calculation of diluted earnings (loss) per share. As of the three and six-month periods ended June 30, 2026 and 2025, the Company excluded the following shares from the calculation of diluted loss per share because such amounts were anti-dilutive: <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl2eKkXLZiK8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies Basis of Presentation (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify">Shares issuable upon conversion of Series B Convertible Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zugjecVobSc4" style="width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zxl9U6rypDX9" style="width: 13%; text-align: right" title="Antidilutive shares">2,407,785</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares issuable upon vesting of Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zRX0IImdGcEj" style="text-align: right" title="Antidilutive shares">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z3sIepAnHALd" style="text-align: right" title="Antidilutive shares">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Shares issuable upon exercise of stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_zh9vyKGqtP8j" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,301,254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_z7UWvoh1KUkj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,431,254</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zsnpMGlbrXqb" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">7,801,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zxF60bltwf04" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">9,839,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zl2eKkXLZiK8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies Basis of Presentation (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of anti-dilutive shares</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify">Shares issuable upon conversion of Series B Convertible Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zugjecVobSc4" style="width: 13%; text-align: right" title="Antidilutive shares">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zxl9U6rypDX9" style="width: 13%; text-align: right" title="Antidilutive shares">2,407,785</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Shares issuable upon vesting of Restricted Stock Units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zRX0IImdGcEj" style="text-align: right" title="Antidilutive shares">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z3sIepAnHALd" style="text-align: right" title="Antidilutive shares">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Shares issuable upon exercise of stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_zh9vyKGqtP8j" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,301,254</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ExerciseOfStockOptionsMember_z7UWvoh1KUkj" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">7,431,254</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260101__20260630_zsnpMGlbrXqb" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">7,801,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250101__20250630_zxF60bltwf04" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">9,839,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2407785

500000

7301254

7431254

7801254

9839039

Fair Value Measurements The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities, as necessary, and to determine fair value disclosures of financial instruments on a recurring basis. Consistent with ASC Topic 820, Fair Value Measurements (“ASC 820”), assets and liabilities that are required to be recorded at fair value are done so at the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. When measuring fair value, and consistent with the fair value hierarchy in ASC 820, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs consistent with the following fair value hierarchy: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to assess at the measurement date.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">Level 3 inputs are unobservable inputs for the asset or liability.</td></tr> </table> For assets and liabilities measured at fair value when there is limited or no observable market data, management applies judgment to estimate fair value and considers factors such as current pricing policy, the economic and competitive environment, the characteristics of the asset or liability, and other factors. The amounts estimated by management cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Inherent limitations in any such fair value calculation technique, including changes in discount rates, estimates of future cash flows, and other underlying assumptions, could significantly affect the results of current or future value.

Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include but are not limited to the applicability of accrued expenses and volatility used in the determination of stock-based expenses. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience. There have been no changes in estimates during the periods presented. Actual results could differ from the Company’s estimates and those differences may be material.

Cash Cash amounts consist of cash on hand, bank deposits, and money market accounts. Cash equivalents consist of all liquid debt instruments with original maturities of three months or less. As of June 30, 2026 and December 31, 2025, the Company’s cash balances were $3,024,044 and $2,772,082, respectively, and the Company’s cash equivalents were $-0- and $-0-, respectively.

3024044

2772082

Subscriptions Receivable and Stock Compensation The Company typically reflects subscriptions receivable in stockholders’ equity, unless there is substantial evidence of the intent and ability of the subscriber to pay the amounts in a reasonable amount of time, in which case the subscriptions receivable are instead reflected as an asset on the balance sheet. There were no subscriptions receivable as of June 30, 2026, or December 31, 2025. The Company reflects stock-based compensation at the intrinsic value of the compensation ratably across the periods in which the compensation is earned. When stock is issued for services, the intrinsic value of the stock issued is amortized ratably over the period in which the compensation is earned. In the initial period of amortization, the amortized portion is reflected in preferred or common stock, as applicable, for both shares and the full par value with any residual reflected in additional paid-in capital. The amortization for each subsequent period is reflected entirely in additional paid-in capital.

Value Added Tax (“VAT Tax”) The Company’s subsidiary historically has paid significant amounts of VAT Tax to the Chilean government on certain operating purchases. The tax paid can be offset against future VAT Tax due. The Company has not recorded any VAT tax receivables as of June 30, 2026 and December 31, 2025, because the Company’s ability to engage in sales activity necessary to recover VAT taxes paid in on its expenditures is currently indeterminable.

Property and Equipment Property, plant, and equipment are stated at cost, less accumulated depreciation. Acquired property, plant and equipment are recognized at their estimated fair value. Capitalized costs may include computers, vehicles, furniture and fixtures, machinery, and equipment, and are depreciated using the straight-line method or unit-of-production method at rates sufficient to depreciate such costs over the shorter of estimated productive lives or the useful life of the individual assets. Useful lives range from 3 to 10 years. Capitalized costs may also include buildings or improvements to land, which if applicable, have useful lives ranging from <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandBuildingsAndImprovementsMember__srt--RangeAxis__srt--MinimumMember_zwSZYfgK9tX3" title="Property and equipment useful lives">20 to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandBuildingsAndImprovementsMember__srt--RangeAxis__srt--MaximumMember_z0xa6nYODdhl" title="Property and equipment useful lives">40 years. Gains and losses are reflected in income or expense upon sale or retirement of assets. Expenditures that extend the useful lives of property, plant and equipment or increase productivity are capitalized. Ordinary repairs and maintenance are expensed as incurred through operating expense. We periodically evaluate whether events or circumstances indicate that the net book value of our property, plant and equipment may not be recoverable. Costs are capitalized when it has been determined an ore body can be economically developed. The development stage begins at new projects when our management and/or board of directors make the decision to bring a mine into commercial production and ends when the production state, or extraction of reserves, begins. The production stage of a mine commences when salable materials, beyond a de minimis amount, are produced. Exploration costs include those relating to activities carried out (a) in search of previously unidentified mineral deposits or (b) at undeveloped concessions. Pre-development activities involve costs incurred in the exploration stage that may ultimately benefit production and are expensed due to a lack of evidence of economic development, which is necessary to demonstrate future recoverability of these expenses. Costs for exploration, evaluation, and pre-development, including drilling costs related to those activities (discussed further below), and repairs and maintenance on capitalized property and equipment are charged to operations as incurred. Drilling, development, and related costs are either classified as exploration, pre-development or secondary development as defined above, and charged to operations as incurred, or capitalized based on the following criteria: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%; text-align: justify">whether the costs are incurred to further define mineralization at and adjacent to existing reserve areas or intended to assist with mine planning within a reserved area;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">whether the drilling or development costs relate to an ore body that has been determined to be commercially mineable, and a decision has been made to put the ore body into commercial production;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">whether, at the time the cost is incurred: (a) the expenditure embodies a probable future benefit that involves a capacity, singly or in combination with other assets, to contribute directly or indirectly to future net cash inflows, (b) we can obtain the benefit and control others’ access to it, and (c) the transaction or event giving risk to our right to or control of the benefit has already occurred.</td></tr> </table> If all of these criteria are met, drilling, development and related costs are capitalized. Drilling and development costs not meeting all of these criteria are expensed as incurred. The following factors are considered in determining whether or not the criteria listed above have been met, and whether capitalization of drilling and development costs is appropriate: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%">Completion of a favorable economic study and mine plan for the ore body targeted;</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td>authorization of development of the ore body by management and/or the board of directors; and</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">there is a justifiable expectation, based on applicable laws and regulations, that issuance of permits or resolution of legal issues and/or contractual requirements necessary for us to have the right to or control of the future benefit from the targeted ore body have been met.</td></tr> </table> Drilling and related costs at our properties as of and for the six-months ended June 30, 2026 and June 30, 2025, respectively, and the three-months ended June 30, 2026 and June 30, 2025, respectively, did not meet our criteria for capitalization. When assets are retired or sold, the costs and related allowances for depreciation and amortization are eliminated from the accounts and any resulting gain or loss is reflected in the current period net income (loss).

P3Y

P10Y

P20Y

P40Y

Impairment of Long-lived Assets Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use and eventual disposition of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value less cost to sell or dispose, determined based on discounted cash flows. During the six-months and three-months ended June 30, 2026 and 2025, we recorded $-0- and $-0-, respectively, impairment losses in those periods. Baltum presently owns 6,377 hectares of exploitation-level mining concessions in the San Juan mining district, which were recorded as fully impaired and written down to $-<span id="xdx_905_eus-gaap--MineralPropertiesAccumulatedImpairment_iI_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--BaltrumMiningConcessionsMember_zkMJRr0FSvAl" title="Impaired and written down">0- value from approximately $1.9 million in September 2025 in aggregate on the Company’s facilities located in the San Juan mining district of Chile and previously wrote down the remainder, based on the lack of reliability of and availability of independent valuations for these unique assets, as necessary to substantiate their value for financial statement purposes. Under a funding level that allows the Company to focus on exploration, Baltum will continue its exploration activities under these mining concessions toward proving the existence of cobalt and/or copper. Depending on the outcome of the exploration activities, the Company would then consider seeking a preliminary economic assessment, preliminary feasibility study, or definitive feasibility study to validate the expected profitability of constructing a plant to extract the target minerals and process them into saleable products.

1900000

Environmental Obligations We provide for environmental-related obligations when they are probable and amounts can be reasonably estimated. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Included in our environmental liabilities are costs for the operation, maintenance and monitoring of site remediation plans (“OM&M”). If applicable, such reserves are based on our best estimates for these OM&M plans. Over time we could incur OM&M costs in excess of these reserves. However, we are unable to reasonably estimate an amount in excess of any recorded reserves because we cannot reasonably estimate the period for which such OM&M plans will need to be in place or the future annual cost of such remediation, as conditions at environmental sites change over time. If applicable, such additional OM&M costs could be significant in total but would be incurred over an extended period of years. Environmental remediation charges represent the costs for continuing charges associated with environmental remediation at operating sites from previous years and from products that are no longer manufactured and are currently not applicable.

Leases The Company determines if an arrangement is a lease at the inception of the contract. If applicable, our operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities – current, and operating lease liabilities – long term in the condensed consolidated balance sheets. The operating lease ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit interest rate, we utilize an estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. In determining the discount rate used in the present value calculation, the Company has elected to apply the portfolio approach for leases provided the leases commenced at or around the same time. This election allows the Company to account for leases at a portfolio level provided that the resulting accounting at this level would not differ materially from the accounting at the individual lease level. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. If leases are applicable, the Company has elected not to separate lease and non-lease components and accounts for each separate lease component and non-lease component associated with that lease component as a single lease component. Operating lease ROU assets include all contractual lease payments and initial direct costs incurred less any lease incentives. Facility leases generally only contain lease expense and non-component items such as taxes and pass-through charges. Additionally, we have elected not to apply the recognition requirements of ASC 842 to leases which have a lease term of less than one year at the commencement date.

Mining Concessions Mining concessions are recorded at cost based on the payments required under the contracts. Amortization begins when placed in service after the mining concession is exercised. Mining concessions are amortized over their useful life based on the pattern over which the mining concessions are consumed or otherwise used up. Determination of expected useful lives for amortization calculations is made on a property-by-property or asset-by-asset basis at least annually. At the time an ore body can be economically developed, the basis of the mining concession will be amortized on a units-of-production basis. Pursuant to our policy on the impairment of long-lived assets, if it is determined that a mining concession cannot be economically developed or its innate value has not been independently substantiated, the basis of the mining concession is reduced to its fair value and an impairment loss is recorded to expense in the period in which it is determined to be impaired. Finite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Intangible assets that are not subject to amortization are tested for impairment annually and more frequently if events or changes in circumstances indicate that is more likely than not (meaning more than 50%) that the asset is impaired. The value of the exploitation mining concessions owned by Baltum has yet to be independently substantiated by a valuation or any level of feasibility study. As of June 30, 2026 and December 31, 2025, these mining concessions had a value of $-0- and $-0-, respectively on the Company’s condensed consolidated balance sheet. 0 0

<p id="xdx_842_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyOngoingBenefitArrangements_zkv7vpj1z4aj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restructuring and Other Charges We continually perform strategic reviews and assess the returns on our businesses. In the event that this results in a plan to restructure the operations of our business, we record an accrual for severance and other exit costs under the provisions of the relevant accounting guidance.

Research and Development Research and development costs are expensed as incurred.

Foreign Currency The reporting currency of the Company is the U.S. dollar. The functional currency of Baltum, the Company’s wholly-owned subsidiary, is the Chilean Peso. The assets and liabilities of Baltum are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive income or loss within the Company’s condensed consolidated balance sheet. Gains and losses resulting from foreign currency transactions are reflected within the Company’s condensed consolidated statements of operations. Transactions denominated in foreign currency other than our functional currency of the foreign operation are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at each reporting date into the functional currency at the exchange rate at that date. The Company has not utilized foreign currency hedging strategies to mitigate the effect of its foreign currency exposure. There were no material transaction and remeasurement gains for the three and six-months ended June 30, 2025 and 2026, respectively.

Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred taxes are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company’s wholly owned subsidiary is subject to foreign corporate tax in foreign taxing jurisdictions. We do not provide income taxes on the equity in undistributed earnings of consolidated foreign subsidiaries as it is our intention that such earnings will remain invested in those companies. The Company accounts for income taxes in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Under ASC 740, income tax expense includes federal and state taxes currently payable and deferred taxes arising from temporary differences between income for financial reporting and income tax purposes. In accordance with ASC 740, the Company has evaluated its tax positions. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that has a likelihood of being realized on examination of more than 50 percent. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Under the “more likely than not” threshold guidelines, the Company believes no significant uncertain tax positions exist, either individually or in the aggregate, that would give rise to the non-recognition of an existing tax benefit. The Company’s policy is to account for interest expense and penalties related to unrecognized tax benefits as a component of income tax expense. The Company is currently not under examination with any federal, state, or foreign taxing authorities. In addition, the Company had no material unrecognized tax benefits or accrued interest and penalties as of and for the six-months ended June 30, 2026.

Concentration of Credit Risk and of Significant Vendors The Company maintains cash balances at financial institutions in the United States and Chile. The Company holds all cash balances at accredited financial institutions, in amounts that exceed federally insured limits in the United States of America. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Segment Reporting The Company has not yet begun generating revenues from its planned principal operations and operates as a single reportable segment for its cobalt-copper / copper-cobalt projects in Chile. The chief operating decision maker is the Company’s chief executive officer, who assesses the performance based on total expenses, cash flows and progress made in the Company’s ongoing development efforts. All of the Company’s long-lived assets are located in Chile.

Recently Issued and Adopted Accounting Pronouncements The Company’s management has evaluated all the recently issued accounting pronouncements through the filing date of these financial statements, including ASC 2023-09, and does not believe that any of these pronouncements will have a material impact on the Company’s current financial position and results of operations.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">4.</td> <td>Other Assets</td></tr> </table> NeoRe Project Under the terms of the January 8, 2026 Binding Earn-in and Option Agreement (the “NeoRe Agreement”) between the Company and NeoRe SpA (“NeoRe”) related to the NeoRe Rare Earth Project in Southern Chile (the “NeoRe Project”), an agreed upon budget was developed whereby the Company pays the monthly budgeted amounts to NeoRe towards earn-in of Net Smelter Return (“NSR”) royalty awards. While funding toward the cap and the accomplishment of tranche 1 and tranche 2 objectives, whether performed in sequence or in parallel, the costs are classified as other assets, whereas, when a 1% NSR royalty award is earned, the cost to achieve the award is re-classified as an NSR Royalty Asset (see footnote 5). The Company is not obligated to make further contributions, but would then be subject to the potential of losing the contributions made toward the tranche 2 NSR royalty, if not already fully earned. As of June 30, 2026 and June 30, 2025, $1,025,757 and $-0- had been paid toward earn-in of the tranche 1 and tranche 2 awards, with $<span id="xdx_901_ecustom--BusinessCombinationContingentConsiderationAssetReclassed_iI_c20260630__us-gaap--BusinessAcquisitionAxis__custom--Tranche1Member_zf49eovknmge" title="Contingent consideration reclassed amount">851,043 of that amount re-classed to NSR Royalty Asset upon earn-in of the tranche 1 award, as discussed in footnote 5, while the remaining $174,714 has been paid toward the earn-in of the tranche 2 award and is classified as “Other Assets” on the Company’s June 30, 2026 balance sheet. Therefore, as of June 30, 2026, this leaves a capped maximum of $<span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationAssetCurrent_iI_c20260630__us-gaap--BusinessAcquisitionAxis__custom--Tranche1Member_zgu1EyFrcNh8" title="Contingent consideration maximum">1,325,286 of contingent consideration for the full acquisition of the tranche 2 <span id="xdx_90E_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_iI_dp_c20260630__us-gaap--BusinessAcquisitionAxis__custom--Tranche2Member_zxvV8vKO2zqf" title="Asset percentage">1% NSR royalty asset. Under the terms of the NeoRe Agreement, the Company may elect to proceed with tranche 3 of the NeoRe Project, and if so, a definitive agreement would be executed with the terms for the Option to acquire the NeoRe Project as outlined in the NeoRe Agreement. If elected, the Company would surrender its earned NSR royalties, issue to the owners of NeoRe the appropriate number of shares of common stock of the Company and take ownership of the NeoRe Project by asset purchase, share purchase, merger or other mutually agreed upon acquisition structure. There are also provisions for bonus shares of the Company’s common stock to be issued, if NeoRe meets certain permitting and production targets. In addition, upon acquiring the NeoRe Project, the Company would be responsible to third-parties for NeoRe introduction fees and warrants issued by NeoRe prior to the execution of the NeoRe Agreement. Currently, the acquisition of the NeoRe Project is still considered a possibility, but not a certainty. Mining Concession Payments On May 12, 2026, the Company executed a Terms of Reference (the “Term Sheet”) with a counter-party that defined the terms agreeable for a potential future option agreement for the acquisition of approximately 1,400 hectares of exploitation-level and approximately <span id="xdx_904_eus-gaap--AreaOfLand_iI_uhectares_c20260512__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ExplorationLevelMiningConcessionsMember_zykf2CyKceK4" title="Hectares of exploitation concessions">2,900 hectares of exploration-level mining concessions in Chile. Subject to the Term Sheet, the Company has advanced $500,000 to the counter-party, which is intended to be applied as a credit against the first required option payment or recoverable if encumbrances or material adverse conditions discovered during the due diligence period are not properly resolved by the counter-party. The total option price varies contingent on the timing of option repayment and the advance amount paid would be credited against the first option payment, leaving $1,500,000 due within 5 business days of the execution of a definitive option agreement, if applicable. The $500,000 advance is classified as “Other Assets” on the Company’s June 30, 2026 balance sheet until the definitive option agreement is signed and the advance is applied against the first required option payment or the amount is refunded or forfeited. In addition, services and fees directly related to the acquisition are being capitalized and will be added to the cost of the acquisition, if the option agreement is exercised and the mining concessions become fully owned by the Company. As of June 30, 2026, $36,078 of capitalized costs related to the mining concession acquisition are posted to “Other Assets” on the Company’s June 30, 2026 balance sheet. Issuance Costs Any costs directly related to the issuance of equity are required to be capitalized and posted as an offset to additional paid in capital, when the issuance of equity occurs, or written off if the issuance of equity does not occur. As of June 30, 2026, $33,114 of capitalized costs related to issuances of equity are posted to “Other Assets” on the Company’s June 30, 2026 balance sheet.

1025757

851043 174714

1325286

0.01

1400

2900

500000

1500000

500000

36078

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">5.</td> <td>NSR Royalty Asset</td></tr> </table> As outlined in footnote 4, under the NeoRe Project section the Company pays monthly budgeted amounts to NeoRe towards the accomplishment of tranche 1 and tranche 2 objectives. The tranche 1 objectives were satisfied as of May 31, 2026 and the first of two 1% NSR Royalty awards was earned by the Company. Upon earning a 1% or two 1% for a total of 2% NSR royalty, the aggregate contribution amounts would either constitute the cost basis upon 3rd-party acquisition of the NSR royalty or amortized over the life of the production from the NeoRe Project that generates NSR Royalty income, if applicable. The amount paid toward the first 1% NSR Royalty award was $851,043, based on monthly budgeted payments made from December 2026 through May 2026. Amounts paid toward completion of tranche 2 objectives and earn-in of the second 1% NSR Royalty award are posted to Other Assets, as indicated in footnote 4.

851043

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">6.</td> <td>Property and Equipment, Net</td></tr> </table> Property and equipment, net consisted of the following: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJQPGNYkDD45" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, Net (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property and equipment, net</td><td> </td> <td colspan="2" id="xdx_497_20260630_zba2InuMGCFg" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20251231_znA9vY8XbwG8" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzeTX_zLrGAYfzraj1" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify; padding-bottom: 1pt">Property and equipment</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">29,583</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">29,583</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzeTX_maPPAENzj8w_zzOGEIwder9c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzj8w_z6BqyB3DYwm2" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,625</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzj8w_zKjIgHAXco0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expenses for the three-months ended June 30, 2026 and June 30, 2025, amounted to $-0- and $-0-, respectively. Loss on retirement of assets for the three-months ended June 30, 2026 and June 30, 2025, amounted to $-0- and $-0-, respectively.

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--PropertyPlantAndEquipmentTextBlock_zJQPGNYkDD45" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment, Net (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of property and equipment, net</td><td> </td> <td colspan="2" id="xdx_497_20260630_zba2InuMGCFg" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49C_20251231_znA9vY8XbwG8" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--MachineryAndEquipmentGross_iI_pp0p0_maPPAEGzeTX_zLrGAYfzraj1" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify; padding-bottom: 1pt">Property and equipment</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">29,583</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">29,583</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzeTX_maPPAENzj8w_zzOGEIwder9c" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,583</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzj8w_z6BqyB3DYwm2" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(26,625</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzj8w_zKjIgHAXco0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

29583

26625

2958

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">7.</td> <td>Accrued Expenses</td></tr> </table> Accrued expenses consisted of the following: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z2wCAe9pART5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of accrued expenses</td><td> </td> <td colspan="2" id="xdx_491_20260630_z1xgKo4YK7i3" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_491_20251231_zYEF94NKXmUi" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzY8z_zuon5b72JJkj" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify">Service fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzY8z_zSPyVvKtqf0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzY8z_zCg4hSxWrY7k" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">371</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">444</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzY8z_z2NYiswe5dz8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,425</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z2wCAe9pART5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses (Details)"> <tr style="vertical-align: bottom"> <td>Schedule of accrued expenses</td><td> </td> <td colspan="2" id="xdx_491_20260630_z1xgKo4YK7i3" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_491_20251231_zYEF94NKXmUi" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCzY8z_zuon5b72JJkj" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%; text-align: justify">Service fees</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">50,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">12,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCzY8z_zSPyVvKtqf0j" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzY8z_zCg4hSxWrY7k" style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">371</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">444</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzY8z_z2NYiswe5dz8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,425</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,044</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

50954

12500

2100

371

444

53425

15044

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">8.</td> <td id="xdx_82C_zfFdVZx8FAjc">Stockholders’ Equity</td></tr> </table> Preferred Stock The Company’s certificate of incorporation authorized the Company to issue 25,000,000 shares of Preferred Stock, $0.0001 par value. On December 28, 2017, a Certificate of Designations was approved by the board of directors that authorized the issuance of 7,500,000 shares of Series A Convertible Preferred Stock, of which 5,151,125 were issued and then subsequently converted into shares of common stock on August 10, 2020. Once converted into shares of common stock, the provisions of the Certificate of Designations do not allow for the re-issuance of such shares of Series A Convertible Preferred Stock. On December 26, 2024, a Certificate of Designations was approved by the board of directors that authorized the issuance of 2,600,000 shares of Series B Convertible Preferred Stock. On December 29, 2024, an amended and restated Certificate of Designations was approved by the board of directors that authorized the issuance of 2,900,000 shares of Series B Convertible Preferred Stock (an increase of 300,000 shares), among other terms and conditions. The Certificate of Designations provided for anti-dilution protection and included a provision that all shares of Series B Convertible Preferred Stock will convert to their common stock equivalent, at a ratio of one share of Series B Convertible Preferred Stock equals one share of Common Stock, subject to adjustments for dividends, splits and/or anti-dilution, as of December 31, 2025. All <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBConvertiblePreferredIntoCommonStockMember_zPwRobLD0f83" title="Stock converted, shares converted">2,407,785 shares of Series B Convertible Preferred Stock converted to common stock on December 31, 2025. 2025 Issuances: During the year ended December 31, 2025, the Company issued the following shares of preferred stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%; text-align: justify">1,683,365 shares of Series B Convertible Preferred Stock were issued to investors at $0.45 per share for total proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TransactionTypeAxis__custom--CashReceivedMember_zuoP2Tv7TnOk" title="Proceeds">757,514. In addition, $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--TransactionTypeAxis__custom--SubscriptionsReceivableMember_z2aNGwkOCm61">73,431 of Subscriptions Receivable were received in cash for an overall total of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z1JuARMXfppa" title="Proceeds">830,945 cash received in 2025.</td></tr> </table> 2026 Issuances: During the six-months ended June 30, 2026, the Company issued no shares of preferred stock. There were <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zAnhKInDedJ3" title="Preferred stock, shares outstanding">no shares of Series A Convertible Preferred Stock outstanding as of June 30, 2026, or December 31, 2025, and <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_ziQwmvUh6Jb2" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zootOZFNDXuj" title="Preferred stock, shares outstanding">no shares of Series B Convertible Preferred Stock outstanding as of June 30, 2026, and December 31, 2025, respectively. Common Stock The Company’s certificate of incorporation authorizes the Company to issue 100,000,000 shares of $0.0001 par value common stock. As of June 30, 2026 and December 31, 2025, there were 57,972,430 and 56,409,930 shares of common stock issued and outstanding. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. 2025 Issuances: During the year ended December 31, 2025, the Company issued the following shares of common stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%; text-align: justify"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pn5n6_c20250101__20251231__srt--CounterpartyNameAxis__custom--CobaltChileSpaMember_zO24yxqoOA77" title="Stock issued for aquisition, shares">4.5 million shares of common stock were issued to Cobalt Chile SpA on September 12, 2025, on behalf of Baltum, for it to acquire 30 full-exploitation mining concessions at the fair value price on the date of issuance of $0.42 per share, which equates to a total acquisition value of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20250101__20251231__srt--CounterpartyNameAxis__custom--CobaltChileSpaMember_znDrnsKvMr7k" title="Stock issued for acquisition, value">1,890,000, as reflected in the supplemental disclosure of non-cash financing activities in the financial statements.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify">6 million shares of common stock were issued to Madesal SpA (4 million shares) and Glencore Ltd (2 million shares) on December 2, 2025, at the fair value price on the date of issuance of $0.50 per share for total gross proceeds of $3,000,000, and after reducing for $247,500 of direct and incremental costs of the raise, there were net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250101__20251231__srt--CounterpartyNameAxis__custom--MadesalSpAAndGlenoreMember_zgBLN4Z5331j" title="Proceeds from issuance of common stock">2,752,500.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>·</td> <td style="text-align: justify"><span id="xdx_902_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20251231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__us-gaap--ConversionOfStockByUniqueDescriptionAxis__custom--SeriesBConvertiblePreferredIntoCommonStockMember_zvsxuPoUtTbj" title="Stock converted, shares converted">2,407,785 shares of Series B Convertible Preferred Stock were converted at one share of common issued for every one share of Series B Convertible Preferred Stock tendered on December 31, 2025, as indicated previously in the “Preferred Stock” section above.</td></tr> </table> 2026 Issuances: During the six-months ended June 30, 2026, the Company issued the following shares of common stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 3%"> </td> <td style="width: 3%">·</td> <td style="width: 94%; text-align: justify">1,562,500 shares of common stock were issued to Glencore Ltd (<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--GlencoreLtdMember_zECgflLHRTBl">1,250,000 shares) and Madesal SpA (<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--CounterpartyNameAxis__custom--MadelsalSpaMember_zlzgAGyqn0A1">312,500 shares) on May 18, 2026, at an issuance price of $1.60 per share for total gross and net proceeds of $2,500,000.</td></tr> </table> Stock Options and Restricted Stock Units On April 26, 2022, the board adopted, and by shareholder consent achieved on April 29, 2022, the shareholders approved the Company’s 2022 Equity Incentive Plan (the “2022 Plan”), which allows awards for up to 5,850,000 options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220426__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2022Member_z9v3BuTnNvXa" title="Shares authorized for issuance under plan">5,850,000 shares of its Common Stock at prevailing fair value exercise prices at the time of each award. There were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260630__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2022Member_zmU2ZiHa91Ng" title="Options available for grant">5,611,254 options to purchase 5,611,254 shares of its Common Stock, net of forfeitures, awarded under the 2022 Plan as of June 30, 2026. The purposes of the 2022 Plan are (i) to attract and retain the best available personnel for positions of substantial responsibility, (ii) to provide additional incentives to Employees, Directors, and Consultants, and (iii) to promote the success of the Company’s business. On May 24, 2022, the Company granted stock options to purchase an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220523__20220524__srt--TitleOfIndividualAxis__custom--OfficersManagersAdvisorsAndDirectorsMember_zLD1itD1NQUf" title="Options granted, shares">5,025,000 shares to officers/management, advisors, and directors at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220523__20220524__srt--TitleOfIndividualAxis__custom--OfficersManagersAdvisorsAndDirectorsMember_pdd" title="Options granted, exercise price">0.20. The options vest quarterly starting on June 30, 2022, for 25% of the granted shares and then the remainder in equal installments over a one-and-one-half-year period and expire in 10 years from the date of the grant. On June 1, 2022, the Company granted stock options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220530__20220601__srt--TitleOfIndividualAxis__custom--AdvisorMember_zDSiKl622R14" title="Options granted, shares">80,004 shares to an advisor at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220530__20220601__srt--TitleOfIndividualAxis__custom--AdvisorMember_zNmHP7yHnq21" title="Options granted, exercise price">0.20. <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220530__20220601__srt--TitleOfIndividualAxis__custom--AdvisorMember_zmFlrrMerZQ8" title="Option terms of award">The options vest quarterly in equal installments over a one-year period and expire 10 years from the date of grant. On July 15, 2022, the Company granted stock options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220714__20220715__srt--TitleOfIndividualAxis__srt--OfficerMember_zTBAJHWdLotc" title="Options granted, shares">450,000 shares to an officer at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220714__20220715__srt--TitleOfIndividualAxis__srt--OfficerMember_z44wBAWbzXEj" title="Options granted, exercise price">0.20. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220714__20220715__srt--TitleOfIndividualAxis__srt--OfficerMember_zHZcC64O9cU6" title="Option terms of award">The options vest quarterly starting on September 30, 2022, for 25% of the granted shares and then the remainder in equal installments over a three-quarter year period and expire in 10 years from the date of grant. On July 28, 2022, the Company granted stock options to purchase an aggregate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220727__20220728__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorMember_zYEvdoLviwy2" title="Options granted, shares">150,000 shares to an officer/director at an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220727__20220728__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorMember_zEeekJ9AKpea" title="Options granted, exercise price">0.20. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20220727__20220728__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorMember_zJoxSGpIeW12" title="Option terms of award">The options vest quarterly starting on September 30, 2022, for 12.5% of the granted shares and then the remainder in equal installments over a one-and-three-quarter-year period and expire in 10 years from the date of grant. On June 29, 2023, the board of directors adopted, and by shareholder consent achieved on June 30, 2023, the shareholders approved the Company’s 2023 Equity Incentive Plan (the “2023 Plan”), which allows awards for up to 1,963,746 options to purchase 1,963,746 shares of its common stock at prevailing fair value exercise prices at the time of each award. There were 1,870,000 options to purchase 1,870,000 shares of its common stock awarded under the 2023 Plan as of June 30, 2026. The purposes of the 2023 Plan were (i) to attract and retain the best available personnel for positions of substantial responsibility, (ii) to provide additional incentives to Employees, Directors, and Consultants, and (iii) to promote the success of the Company’s business. On July 1, 2023, the Company granted stock options to purchase an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230628__20230701__srt--CounterpartyNameAxis__custom--OfficersManagementAndDirectorsMember_z7h0I1Ls5n3h" title="Options granted, shares">750,000 shares to officers/management and directors at an exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230628__20230701__srt--CounterpartyNameAxis__custom--OfficersManagementAndDirectorsMember_zY4yistZboji" title="Options granted, exercise price">0.26. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20230628__20230701__srt--CounterpartyNameAxis__custom--OfficersManagementAndDirectorsMember_zUiVtkPfblme" title="Option terms of award">The options vest quarterly starting on October 1, 2023, in equal installments over a two-year period and expire in 10 years from the date of grant. On July 7, 2023, the Company granted stock options to purchase an aggregate of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230706__20230707__srt--CounterpartyNameAxis__custom--DirectorsMember_zqrtqwZjeW9b" title="Options granted, shares">300,000 shares to directors at an exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230706__20230707__srt--CounterpartyNameAxis__custom--DirectorsMember_pdd" title="Options granted, exercise price">0.26. The options vest quarterly starting on October 1, 2023, for 12.5% of the granted shares and then the remainder in equal installments over a one-and-one-half-year period and expire in 10 years from the date of grant. On January 25, 2024, the Company granted stock options to purchase an aggregate of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240124__20240125__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember_zis2QwrdKmJ9" title="Options granted, shares">75,000 shares to advisory board members at an exercise price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240124__20240125__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember_pdd" title="Options granted, exercise price">0.26. The options vest quarterly starting on March 31, 2024, for 25% of the granted shares and then the remainder in equal installments at each quarter-end through the end of 2024 and expire in 10 years from the date of grant. On February 13, 2024, the Company granted stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240212__20240213__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember_zD8Vt04pS8Sf" title="Options granted, shares">50,000 shares to an advisory board member at an exercise price of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240212__20240213__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember_pdd" title="Options granted, exercise price">0.26. The options vest quarterly starting on March 31, 2024, for 25% of the granted shares and then the remainder in equal installments at each quarter-end through the end of 2024 and expire in 10 years from the date of grant. On January 17, 2025, the Company granted stock options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250116__20250117__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndAdvisoryBoardMember_zJJN4Zd81opb" title="Options granted, shares">645,000 shares to officers/management, directors, contractors and advisory board members at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250116__20250117__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndAdvisoryBoardMember_zI69mneLn9x1" title="Options granted, exercise price">0.50. The <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250116__20250117__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndAdvisoryBoardMember__us-gaap--VestingAxis__custom--Vesting125GrantedSharesMember_zgFP5ZsYM0hi" title="Options granted, shares">570,000 options awarded to officers/management, directors and contractors vest quarterly starting on March 31, 2025, for 12.5% of the granted shares and then the remainder in equal installments at each quarter-end through the end of 2026 and expire <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20260101__20260630__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndAdvisoryBoardMember_zRiUFHQ3fQOl" title="Expiration years">10 years from the date of grant. The <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250116__20250117__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndAdvisoryBoardMember__us-gaap--VestingAxis__custom--Vesting25GrantedSharesMember_zDC4IDiFs7b8" title="Options granted, shares">75,000 options awarded to advisory board members vest quarterly starting on March 31, 2025, for 25% of the granted shares and then the remainder in equal installments at each quarter-end through the end of 2025 and expire in <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20260101__20260630__srt--TitleOfIndividualAxis__custom--AdvisoryBoardMember_zKsUfEVgV7Th" title="Expiration years">10 years from the date of grant. On July 29, 2025, the Company granted stock options to purchase an aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20250728__20250729__srt--TitleOfIndividualAxis__srt--DirectorMember_zYUp4QAROVqk" title="Options granted, shares">50,000 shares to a director at an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250728__20250729__srt--TitleOfIndividualAxis__srt--DirectorMember_zW3WunNcjTJ8" title="Options granted, exercise price">0.37. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20250728__20250729__srt--TitleOfIndividualAxis__srt--DirectorMember_zf0w6vlOpCB5" title="Option terms of award">The 50,000 options awarded to the director vested in full immediately upon award and expire in 10 years from the date of grant. On July 24, 2025, the board of directors approved, and by shareholder consent achieved on August 27, 2025, the shareholders adopted the Company’s 2025 Equity Incentive Plan (the “2025 Plan”), which allows awards for up to 5,000,000 shares of its common stock to be awarded in various equity incentive formats at prevailing fair value exercise prices at the time of each award. There were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250725__20260630__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2025Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zv2CMm5eiQz5" title="Shares granted">500,000 Restricted Stock Units (RSUs) related to its common stock awarded under the 2025 Plan as of June 30, 2026. The purposes of the 2025 Plan are (i) to attract and retain the best available personnel for positions of substantial responsibility, (ii) to provide additional incentives to Employees, Directors, and Consultants, and (iii) to promote the success of the Company’s business. On August 28, 2025, the Company granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250827__20250828__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2025Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--ADirectorMember_zHeUrGpqFzG6" title="Granted shares">500,000 RSUs related to its common stock to a director. The RSUs all vest on July 27, 2027, assuming the Plan Administrator has not accelerated the vesting for any reason and the director is still actively delivering services under the Consulting and Advisory Agreement between director and Company. Stock Options: The fair value of the options granted was estimated on the date of grant using the Black-Scholes options pricing model, with the following weighted average assumptions: <table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zI8uQo406Rb6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used for valuating options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> </tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">As of June 30, 2025</td><td style="padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 82%; text-align: justify">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">0.00%</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected stock volatility (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.43%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.027%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__srt--RangeAxis__srt--MinimumMember_zMAbhAEoDhZd" title="Expected life of options (years)">3.00 - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__srt--RangeAxis__srt--MaximumMember_zXDSSQyu9DAc" title="Expected life of options (years)">5.00</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Grant date fair value range per option issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__srt--RangeAxis__srt--MinimumMember_z11tdjj6qIBj" title="Grant date fair value per option">0.3405 - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__srt--RangeAxis__srt--MaximumMember_zZCpO6HUdmXh" title="Grant date fair value per option">0.4020</td><td style="text-align: left"> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%">(a)</td> <td style="width: 95%; text-align: justify">At the time of determination of expected stock volatility, the Company’s securities were trading over-the-counter as an OTCQB traded stock, but for less than two years and under limited trading volume such that calculated volatility based solely on the Company’s volatility isn’t necessarily indicative of the expected volatility over the expected life of the options and RSUs. Therefore, the expected stock volatility was estimated using three public companies in the same industry as the Company and calculating an equal-weighted and blended volatility of the Company’s volatility and the volatility of those three believed-to-be-representative companies over the same period.</td></tr> </table> During the six-months ended June 30, 2026, and June 30, 2025, the Company recorded option-related stock-based compensation expenses of $49,208 and $110,435, respectively, and during the three-months ended June 30, 2026, and June 30, 2025, the Company recorded option-related stock-based compensation expenses of $24,604 and $55,219, respectively. As of June 30, 2026, the unamortized stock option expense was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYeydxc2YAq7" title="Unamortized stock option expense">49,208. The Company’s stock options had an intrinsic value of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_pp0p0_c20260630__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z6HzUCt257Xb" title="Stock options intrinsic value">14,520,133, based on the OTCQB published closing price for (OTCQB: COBA) of $2.190 per share as of June 30, 2026, which may not be indicative of the fair market value of the stock options given the limited historical volumes traded and the volatility of the underlying shares as of that date. Stock-based compensation expense is measured at the date of grant, based on the fair value of the award, and is recognized over the vesting period of the option. The Company recognizes forfeitures in stock-based compensation expense as they occur. A summary of the changes in stock options outstanding at June 30, 2026, are presented below: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWnbgVZUFxGa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Option activity)"> <tr style="vertical-align: bottom"> <td> Schedule of changes in stock options outstanding </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options Outstanding Number of Shares</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%">Balance, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zFymx83L1tY2" title="Options outstanding number of shares, Beginning balance">6,786,254</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zuvj9ouOGO5h" title="Weighted average exercise price, Beginning balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">645,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zT0EvUJq0Jk7" title="Weighted average exercise price, Options issued">0.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(56,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zPzGdcU63Ku" title="Weighted average exercise price, Expired/Forfeited">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zUsQPbkhHHoe" title="Options outstanding number of shares, Beginning balance">7,425,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zfXGyqAR1wmj" title="Weighted average exercise price, Beginning balance">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td>Balance, March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260401__20260630_zfVnCugQGUn5" title="Options outstanding number of shares, Beginning balance">7,425,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260401__20260630_zHaciqltbOW3" title="Weighted average exercise price, Beginning balance">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,425,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260401__20260630_z0KrbFIf7j5j" title="Weighted average exercise price, Ending balance">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company has the following options outstanding and exercisable at June 30, 2026 and 2025: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zJkERuZzmGDi" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Options by price)"> <tr style="vertical-align: bottom"> <td> Schedule of options outstanding and exercisable</td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 14%"><span id="xdx_90B_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z1UWratwTlPj" title="Option issue date">May 24, 2022</td><td style="width: 1%"> </td> <td style="width: 13%"><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zQpt4xQO95fl" title="Option expiration date">May 24, 2032</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_znqUVpiGmDX" style="width: 5%; text-align: right" title="Option exercise price">0.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zWiayGvO4As1" style="width: 7%; text-align: right" title="Options outstanding">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zdEwjkXyIlSg" style="width: 7%; text-align: right" title="Options exercisable">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_ziTqG5K4uxsa" title="Remaining life">5.91</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z5stILgnvvQc" style="width: 5%; text-align: right" title="Option exercise price">0.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zuMQhpxgBzd9" style="width: 7%; text-align: right" title="Options outstanding">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z7pfn0kD4MOl" style="width: 7%; text-align: right" title="Options exercisable">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zHXC9BaGejal" title="Remaining life">6.91</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_908_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zCAlj3X26Pbb" title="Option issue date">June 1, 2022</td><td> </td> <td><span id="xdx_901_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zbeqFDSiO2y1" title="Option expiration date">June 1, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zIdivxHZraQ7" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zINmP95WA9Mg" style="text-align: right" title="Options outstanding">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zEaF8cShDJj7" style="text-align: right" title="Options exercisable">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_z2mrodqB9sE3" title="Remaining life">5.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zuiwEYMlEcJg" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zFbGxuPScqhj" style="text-align: right" title="Options outstanding">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zxYotlrjlPNl" style="text-align: right" title="Options exercisable">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_z59IjGf4jcCc" title="Remaining life">6.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_90B_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zwQUYL0H9C2a" title="Option issue date">July 15, 2022</td><td> </td> <td><span id="xdx_909_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zPLRLZ5IVEG9" title="Option expiration date">July 15, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zRQ5DbqY1RZc" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zHdy3XrOs5eb" style="text-align: right" title="Options outstanding">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zTwvCkUGOFL3" style="text-align: right" title="Options exercisable">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zWGHLPEXV7Bk" title="Remaining life">6.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zIBdud09qfQb" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zUB1pBc506u3" style="text-align: right" title="Options outstanding">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zqJHAdcywhNi" style="text-align: right" title="Options exercisable">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zHhM45GAgph7" title="Remaining life">7.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_904_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zuGB6Cpys5G" title="Option issue date">July 28, 2022</td><td> </td> <td><span id="xdx_908_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zT1DHw4zDd0h" title="Option expiration date">July 28, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_ziiIKD2Kunv4" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zGkYch1AQox1" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_znWq9cYJ1N61" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zV3z5Z64XTK" title="Remaining life">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_z2z8cfhE237j" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_ztnddhQa7hza" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zjhWNa47l5ij" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_z1uIgXjAPcL8" title="Remaining life">7.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_906_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zD2GaelS4du4" title="Option issue date">July 1, 2023</td><td> </td> <td><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zIsv5cxGVVm1" title="Option expiration date">July 1, 2033</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zBp2cABxksM5" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zlGSpEU7p2Qj" style="text-align: right" title="Options outstanding">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zkycaocjNaFh" style="text-align: right" title="Options exercisable">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_z6eFqLufMwi3" title="Remaining life">7.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zIMHkTng7P17" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zVrEyEadLYSj" style="text-align: right" title="Options outstanding">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zesh5Cp0Uqgc" style="text-align: right" title="Options exercisable">412,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zFOUsaFhEDDi" title="Remaining life">8.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_905_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zBti9hglI2ig" title="Option issue date">July 7, 2023</td><td> </td> <td><span id="xdx_90F_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zssWAmHtJ9Zd" title="Option expiration date">July 7, 2033</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zyIjd5yaWep5" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zFoZVcRXONDj" style="text-align: right" title="Options outstanding">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zBYYu7tbr19d" style="text-align: right" title="Options exercisable">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zATjOHCRIXod" title="Remaining life">7.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zuhgFkNz2P1b" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_z3FVpEa79QT7" style="text-align: right" title="Options outstanding">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zDIJYi0l1Ljd" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zra5zYcA1pQd" title="Remaining life">8.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_909_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zKubxEJLlxrd" title="Option issue date">January 25, 2024</td><td> </td> <td><span id="xdx_901_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zfECEqHGvCeb" title="Option expiration date">January 25, 2034</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zQSUnYOsRh3k" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zIZxP3hiFPi8" style="text-align: right" title="Options outstanding">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zBUPAcAj7e1f" style="text-align: right" title="Options exercisable">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zFAUDrkO2On9" title="Remaining life">7.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zmx0JjetvoU9" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zg6gjeWQJFR1" style="text-align: right" title="Options outstanding">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zH0Ejsl2JEP9" style="text-align: right" title="Options exercisable">56,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zjERiX3IBqYd" title="Remaining life">8.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_907_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zzJX9KhhGL46" title="Option issue date">February 13, 2024</td><td> </td> <td><span id="xdx_909_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z8DZKdTgMqa8" title="Option expiration date">February 13, 2034</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z6T7QxVQQHC7" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z1q4lJ3MmpM9" style="text-align: right" title="Options outstanding">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zaWtB9UC6Oij" style="text-align: right" title="Options exercisable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zHOJsNDlJBLa" title="Remaining life">7.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z7WniBGxxhZ3" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zxHMO7r8wxbe" style="text-align: right" title="Options outstanding">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z4Sb4PnUxWKj" style="text-align: right" title="Options exercisable">37,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_ze3xQaZJiO0k" title="Remaining life">8.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_902_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zq0oL6XVNyuj" title="Option issue date">January 17, 2025</td><td> </td> <td><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zDAEkOAfpzu1" title="Option expiration date">January 17, 2035</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zLgTat42jB0e" style="text-align: right" title="Option exercise price">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_ztlGYfu54Vld" style="text-align: right" title="Options outstanding">588,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zkgtgJHKyXhe" style="text-align: right" title="Options exercisable">465,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zLuOCNFXgzaj" title="Remaining life">8.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zvQypS0QjaGf" style="text-align: right" title="Option exercise price">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zifPDNgiLdrj" style="text-align: right" title="Options outstanding">645,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zC82eZZTlSfg" style="text-align: right" title="Options exercisable">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_z5bWHK3I90o1" title="Remaining life">9.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_900_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zmwLvCHy1QC5" title="Option issue date">July 29, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span id="xdx_90C_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zFmZDpmwUi2a" title="Option expiration date">July 29, 2035</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z12QgRrcqiph" style="padding-bottom: 1pt; text-align: right" title="Option exercise price">0.37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zBUkJPzr1ca1" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zPQJUCpNd4Qb" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z5CjT6RsVydh" title="Remaining life">9.09</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">n/a </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_d0_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z71P1HXbezY9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_d0_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zwHrbUoDcrp7" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td colspan="3" style="text-align: left; padding-bottom: 2.5pt">Totals and Weighted Averages Outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630_zOCVXGnp8kS6" style="padding-bottom: 2.5pt; text-align: right" title="Option exercise price">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630_zXjsmFk01Cci" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">7,425,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630_z6cP6FwmdS9e" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">7,301,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">6.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630_zUjnSxSGCzee" style="padding-bottom: 2.5pt; text-align: right" title="Option exercise price">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630_ze4R8xpvT3Gj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">7,431,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zxPNIvTXApH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">6,632,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">7.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Restricted Stock Units (RSUs): The fair value of the <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20250827__20250828__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ziV8vBTvBWTl">500,000 RSUs granted was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20250827__20250828__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjWKSsU7404c" title="Fair value of stock granted">217,500, based on the closing price of $0.435 per share on the grant date of August 28, 2025. During the six-months ended June 30, 2026 and June 30, 2025, the Company recorded RSU-related stock-based compensation expenses of $56,410 and $-0-, respectively, and during the three-months ended June 30, 2026 and June 30, 2025, the Company recorded RSU-related stock-based compensation expenses of $28,205 and $-0-, respectively. As of June 30, 2026, the unamortized RSU expense was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoOpd3ZeMsje" title="Unamortized RSU expense">121,883. The Company’s RSUs had an intrinsic value of $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVNvnHqASID5" title="Intrinsic value">1,095,000, based on the OTCQB published closing price of $2.19 per share as of June 30, 2026, which may not be indicative of the true market value of the stock options given the limited historical volumes traded and the volatility of the underlying shares as of that date. Stock-based compensation expense is measured at the date of grant, based on the fair value of the award, and is recognized over the vesting period of the option. The Company recognizes forfeitures in stock-based compensation expense as they occur.

25000000

0.0001

2600000

2900000

2407785

1683365

757514

73431

830945

100000000

0.0001

57972430

56409930

4500000

1890000

6000000

247500

2752500

2407785

1562500

1250000

312500

5850000

5611254

5025000

0.20

80004

0.20

The options vest quarterly in equal installments over a one-year period and expire 10 years from the date of grant.

450000

0.20

The options vest quarterly starting on September 30, 2022, for 25% of the granted shares and then the remainder in equal installments over a three-quarter year period and expire in 10 years from the date of grant.

150000

0.20

The options vest quarterly starting on September 30, 2022, for 12.5% of the granted shares and then the remainder in equal installments over a one-and-three-quarter-year period and expire in 10 years from the date of grant.

1963746

1870000

750000

0.26

The options vest quarterly starting on October 1, 2023, in equal installments over a two-year period and expire in 10 years from the date of grant.

300000

0.26

The options vest quarterly starting on October 1, 2023, for 12.5% of the granted shares and then the remainder in equal installments over a one-and-one-half-year period and expire in 10 years from the date of grant.

75000

0.26

The options vest quarterly starting on March 31, 2024, for 25% of the granted shares and then the remainder in equal installments at each quarter-end through the end of 2024 and expire in 10 years from the date of grant.

50000

0.26

645000

0.50

570000

P10Y

75000

P10Y

50000

0.37

The 50,000 options awarded to the director vested in full immediately upon award and expire in 10 years from the date of grant.

5000000

500000

<table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zI8uQo406Rb6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Assumptions)"> <tr style="vertical-align: bottom"> <td>Schedule of assumptions used for valuating options</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> </tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">As of June 30, 2025</td><td style="padding-bottom: 1pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 82%; text-align: justify">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">0.00%</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected stock volatility (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.43%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.027%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life of options (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__srt--RangeAxis__srt--MinimumMember_zMAbhAEoDhZd" title="Expected life of options (years)">3.00 - <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__srt--RangeAxis__srt--MaximumMember_zXDSSQyu9DAc" title="Expected life of options (years)">5.00</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="text-align: justify">Expected forfeiture rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00%</td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Grant date fair value range per option issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__srt--RangeAxis__srt--MinimumMember_z11tdjj6qIBj" title="Grant date fair value per option">0.3405 - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20250101__20250630__srt--RangeAxis__srt--MaximumMember_zZCpO6HUdmXh" title="Grant date fair value per option">0.4020</td><td style="text-align: left"> </td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"> </td> <td style="width: 3%">(a)</td> <td style="width: 95%; text-align: justify">At the time of determination of expected stock volatility, the Company’s securities were trading over-the-counter as an OTCQB traded stock, but for less than two years and under limited trading volume such that calculated volatility based solely on the Company’s volatility isn’t necessarily indicative of the expected volatility over the expected life of the options and RSUs. Therefore, the expected stock volatility was estimated using three public companies in the same industry as the Company and calculating an equal-weighted and blended volatility of the Company’s volatility and the volatility of those three believed-to-be-representative companies over the same period.</td></tr> </table>

0.0000

1.1043

0.04027

P3Y

P5Y

0.0000

0.3405

0.4020

49208

110435

24604

55219

49208

14520133

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zWnbgVZUFxGa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Option activity)"> <tr style="vertical-align: bottom"> <td> Schedule of changes in stock options outstanding </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options Outstanding Number of Shares</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 66%">Balance, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250101__20251231_zFymx83L1tY2" title="Options outstanding number of shares, Beginning balance">6,786,254</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20251231_zuvj9ouOGO5h" title="Weighted average exercise price, Beginning balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">645,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zT0EvUJq0Jk7" title="Weighted average exercise price, Options issued">0.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(56,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20251231_zPzGdcU63Ku" title="Weighted average exercise price, Expired/Forfeited">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td>Balance, December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zUsQPbkhHHoe" title="Options outstanding number of shares, Beginning balance">7,425,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zfXGyqAR1wmj" title="Weighted average exercise price, Beginning balance">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td>Balance, March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260401__20260630_zfVnCugQGUn5" title="Options outstanding number of shares, Beginning balance">7,425,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260401__20260630_zHaciqltbOW3" title="Weighted average exercise price, Beginning balance">0.23</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-left: 10pt">Expired/Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">n/a</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="padding-bottom: 2.5pt">Balance, June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,425,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260401__20260630_z0KrbFIf7j5j" title="Weighted average exercise price, Ending balance">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6786254

0.21

645000

0.49

56250

0.50

7425004

0.23

-0

7425004

0.23

-0

7425004

0.23

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zJkERuZzmGDi" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details - Options by price)"> <tr style="vertical-align: bottom"> <td> Schedule of options outstanding and exercisable</td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Issue Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold">Expiry Date</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td style="width: 14%"><span id="xdx_90B_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z1UWratwTlPj" title="Option issue date">May 24, 2022</td><td style="width: 1%"> </td> <td style="width: 13%"><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zQpt4xQO95fl" title="Option expiration date">May 24, 2032</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_znqUVpiGmDX" style="width: 5%; text-align: right" title="Option exercise price">0.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zWiayGvO4As1" style="width: 7%; text-align: right" title="Options outstanding">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zdEwjkXyIlSg" style="width: 7%; text-align: right" title="Options exercisable">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_ziTqG5K4uxsa" title="Remaining life">5.91</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z5stILgnvvQc" style="width: 5%; text-align: right" title="Option exercise price">0.20</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zuMQhpxgBzd9" style="width: 7%; text-align: right" title="Options outstanding">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_z7pfn0kD4MOl" style="width: 7%; text-align: right" title="Options exercisable">4,931,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 5%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedMay242022Member_zHXC9BaGejal" title="Remaining life">6.91</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_908_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zCAlj3X26Pbb" title="Option issue date">June 1, 2022</td><td> </td> <td><span id="xdx_901_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zbeqFDSiO2y1" title="Option expiration date">June 1, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zIdivxHZraQ7" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zINmP95WA9Mg" style="text-align: right" title="Options outstanding">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zEaF8cShDJj7" style="text-align: right" title="Options exercisable">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_z2mrodqB9sE3" title="Remaining life">5.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zuiwEYMlEcJg" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zFbGxuPScqhj" style="text-align: right" title="Options outstanding">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_zxYotlrjlPNl" style="text-align: right" title="Options exercisable">80,004</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJune012022Member_z59IjGf4jcCc" title="Remaining life">6.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_90B_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zwQUYL0H9C2a" title="Option issue date">July 15, 2022</td><td> </td> <td><span id="xdx_909_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zPLRLZ5IVEG9" title="Option expiration date">July 15, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zRQ5DbqY1RZc" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zHdy3XrOs5eb" style="text-align: right" title="Options outstanding">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zTwvCkUGOFL3" style="text-align: right" title="Options exercisable">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zWGHLPEXV7Bk" title="Remaining life">6.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zIBdud09qfQb" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zUB1pBc506u3" style="text-align: right" title="Options outstanding">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zqJHAdcywhNi" style="text-align: right" title="Options exercisable">450,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly152022Member_zHhM45GAgph7" title="Remaining life">7.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_904_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zuGB6Cpys5G" title="Option issue date">July 28, 2022</td><td> </td> <td><span id="xdx_908_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zT1DHw4zDd0h" title="Option expiration date">July 28, 2032</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_ziiIKD2Kunv4" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zGkYch1AQox1" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_znWq9cYJ1N61" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zV3z5Z64XTK" title="Remaining life">6.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_z2z8cfhE237j" style="text-align: right" title="Option exercise price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_ztnddhQa7hza" style="text-align: right" title="Options outstanding">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_zjhWNa47l5ij" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly282022Member_z1uIgXjAPcL8" title="Remaining life">7.08</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_906_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zD2GaelS4du4" title="Option issue date">July 1, 2023</td><td> </td> <td><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zIsv5cxGVVm1" title="Option expiration date">July 1, 2033</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zBp2cABxksM5" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zlGSpEU7p2Qj" style="text-align: right" title="Options outstanding">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zkycaocjNaFh" style="text-align: right" title="Options exercisable">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_z6eFqLufMwi3" title="Remaining life">7.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zIMHkTng7P17" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zVrEyEadLYSj" style="text-align: right" title="Options outstanding">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zesh5Cp0Uqgc" style="text-align: right" title="Options exercisable">412,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly012023Member_zFOUsaFhEDDi" title="Remaining life">8.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_905_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zBti9hglI2ig" title="Option issue date">July 7, 2023</td><td> </td> <td><span id="xdx_90F_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zssWAmHtJ9Zd" title="Option expiration date">July 7, 2033</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zyIjd5yaWep5" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zFoZVcRXONDj" style="text-align: right" title="Options outstanding">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zBYYu7tbr19d" style="text-align: right" title="Options exercisable">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zATjOHCRIXod" title="Remaining life">7.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zuhgFkNz2P1b" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_z3FVpEa79QT7" style="text-align: right" title="Options outstanding">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zDIJYi0l1Ljd" style="text-align: right" title="Options exercisable">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly072023Member_zra5zYcA1pQd" title="Remaining life">8.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_909_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zKubxEJLlxrd" title="Option issue date">January 25, 2024</td><td> </td> <td><span id="xdx_901_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zfECEqHGvCeb" title="Option expiration date">January 25, 2034</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zQSUnYOsRh3k" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zIZxP3hiFPi8" style="text-align: right" title="Options outstanding">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zBUPAcAj7e1f" style="text-align: right" title="Options exercisable">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zFAUDrkO2On9" title="Remaining life">7.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zmx0JjetvoU9" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zg6gjeWQJFR1" style="text-align: right" title="Options outstanding">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zH0Ejsl2JEP9" style="text-align: right" title="Options exercisable">56,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan252024Member_zjERiX3IBqYd" title="Remaining life">8.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_907_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zzJX9KhhGL46" title="Option issue date">February 13, 2024</td><td> </td> <td><span id="xdx_909_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z8DZKdTgMqa8" title="Option expiration date">February 13, 2034</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z6T7QxVQQHC7" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z1q4lJ3MmpM9" style="text-align: right" title="Options outstanding">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zaWtB9UC6Oij" style="text-align: right" title="Options exercisable">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zHOJsNDlJBLa" title="Remaining life">7.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z7WniBGxxhZ3" style="text-align: right" title="Option exercise price">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_zxHMO7r8wxbe" style="text-align: right" title="Options outstanding">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_z4Sb4PnUxWKj" style="text-align: right" title="Options exercisable">37,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedFeb132024Member_ze3xQaZJiO0k" title="Remaining life">8.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td><span id="xdx_902_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zq0oL6XVNyuj" title="Option issue date">January 17, 2025</td><td> </td> <td><span id="xdx_900_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zDAEkOAfpzu1" title="Option expiration date">January 17, 2035</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zLgTat42jB0e" style="text-align: right" title="Option exercise price">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_ztlGYfu54Vld" style="text-align: right" title="Options outstanding">588,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zkgtgJHKyXhe" style="text-align: right" title="Options exercisable">465,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zLuOCNFXgzaj" title="Remaining life">8.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zvQypS0QjaGf" style="text-align: right" title="Option exercise price">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zifPDNgiLdrj" style="text-align: right" title="Options outstanding">645,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_zC82eZZTlSfg" style="text-align: right" title="Options exercisable">90,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJan172025Member_z5bWHK3I90o1" title="Remaining life">9.56</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"><span id="xdx_900_ecustom--OptionIssueDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zmwLvCHy1QC5" title="Option issue date">July 29, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"><span id="xdx_90C_ecustom--OptionExpiryDate_dd_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zFmZDpmwUi2a" title="Option expiration date">July 29, 2035</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z12QgRrcqiph" style="padding-bottom: 1pt; text-align: right" title="Option exercise price">0.37</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zBUkJPzr1ca1" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zPQJUCpNd4Qb" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z5CjT6RsVydh" title="Remaining life">9.09</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">n/a </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_d0_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_z71P1HXbezY9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_d0_c20250630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsIssuedJuly292025Member_zwHrbUoDcrp7" style="border-bottom: Black 1pt solid; text-align: right" title="Options exercisable">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">n/a</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,255,255)"> <td colspan="3" style="text-align: left; padding-bottom: 2.5pt">Totals and Weighted Averages Outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20260630_zOCVXGnp8kS6" style="padding-bottom: 2.5pt; text-align: right" title="Option exercise price">0.23</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630_zXjsmFk01Cci" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">7,425,004</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630_z6cP6FwmdS9e" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">7,301,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">6.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630_zUjnSxSGCzee" style="padding-bottom: 2.5pt; text-align: right" title="Option exercise price">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630_ze4R8xpvT3Gj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">7,431,254</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zxPNIvTXApH9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable">6,632,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">7.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2022-05-24 2032-05-24

0.20

4931250

P5Y10M28D

0.20

4931250

P6Y10M28D

2022-06-01 2032-06-01

0.20

80004

P5Y11M4D

0.20

80004

P6Y11M4D

2022-07-15 2032-07-15

0.20

450000

P6Y18D

0.20

450000

P7Y18D

2022-07-28 2032-07-28

0.20

150000

P6Y29D

0.20

150000

P7Y29D

2023-07-01 2033-07-01

0.26

750000

P7Y3D

0.26

750000

412500

P8Y3D

2023-07-07 2033-07-07

0.26

300000

P7Y10D

0.26

300000

150000

P8Y10D

2024-01-25 2034-01-25

0.26

75000

P7Y6M29D

0.26

75000

56250

P8Y6M29D

2024-02-13 2034-02-13

0.26

50000

P7Y7M17D

0.26

50000

37500

P8Y7M17D

2025-01-17 2035-01-17

0.50

588750

465000

P8Y6M21D

0.50

645000

90000

P9Y6M21D

2025-07-29 2035-07-29

0.37

50000

P9Y1M2D

0.23

7425004

7301254

P6Y4M2D

0.21

7431254

6632504

P7Y3M29D

500000

217500

56410

28205

121883

1095000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">9.</td> <td id="xdx_820_zBOEfJbNCG3c">Commitments and Contingencies, Indemnification Agreements</td></tr> </table> On January 6, 2026, CORFO (the Chilean Economic Development Agency) officially announced the selection of the project entitled “Sustainable Cobalt: A Semi-Industrial Validation of the Green Cobalt Biotechnological Process Integrated with an Extractive Metallurgical Strategy Focused on Tailings and Circular Mining” (the “CORFO Project”) for a $3,000,000 R&D Contribution (the “Grant”), which is to be funded by Albemarle Limitada under agreement with CORFO to support research and development programs vetted and approved by CORFO. The CORFO Project objective is to recover marketable volumes of cobalt product from tailings and mining waste. The Company is one participant in a consortium of industry sponsors for the CORFO Project and has committed to providing $200,000 overall support consisting of half monetary and half in-kind support over the expected three-year project timeline. The Company’s support equates to approximately 21% of the overall consortium-required support contribution of $950,000 toward the CORFO Project. The other key participants in the consortium are Universidad Andres Belo, through its Center for Systems Biotechnology, Pucobre (SSE: PUCOBRE), a Chilean copper mining company listed on the Santiago Stock Exchange, and ENAMI, Chile’s state-owned mining company. The consortium arrangement is considered an executory contract under ASC Topic 440, Commitments (“ASC 440”), which only allows for a liability to be recorded when performance occurs. As there has been no tangible progress on the project as of June 30, 2026, there has been no performance and no liability applicable for this commitment under ASC 440. When project progress is applicable, the Company will record an appropriate liability and expense to research and development for the prorated progress toward project completion. As payments in cash or in-kind are made toward the obligation, they will be recorded as a credit to cash or expense with a corresponding debit to the progress liability. As of June 30, 2026, there have been no cash or in-kind payments toward the project. There has been no formal commitment payment schedule provided to the Company by the consortium, which is currently establishing the legal entity for the project, and then will be able to fulfill the other administrative project prerequisites with project inception expected near the end of 2026 or early 2027. Once technical work is commenced the Company expects the commitment to be consistent from year to year, and therefore projects approximately $<span id="xdx_90C_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_c20260630__us-gaap--OtherCommitmentsAxis__custom--CORFOMember__us-gaap--TransactionTypeAxis__us-gaap--CashMember_zSmYmBTJVLSk" title="Commitment, next twelve months">33,000 and $<span id="xdx_90F_eus-gaap--OtherCommitmentDueInNextTwelveMonths_iI_c20260630__us-gaap--OtherCommitmentsAxis__custom--CORFOMember__us-gaap--TransactionTypeAxis__custom--InKindContributionsMember_zrclF1joIz0a" title="Commitment, next twelve months">33,000 for cash and in-kind contributions, respectively, in 2027; approximately $<span id="xdx_901_eus-gaap--OtherCommitmentDueInSecondYear_iI_c20260630__us-gaap--OtherCommitmentsAxis__custom--CORFOMember__us-gaap--TransactionTypeAxis__us-gaap--CashMember_zuF1A55GmZI" title="Commitment, 2028">33,000 and $33,000 for cash and in-kind contributions, respectively, in 2028; and approximately $<span id="xdx_90B_eus-gaap--OtherCommitmentDueInThirdYear_iI_c20260630__us-gaap--OtherCommitmentsAxis__custom--CORFOMember__us-gaap--TransactionTypeAxis__us-gaap--CashMember_z8qyRqks3Lnf" title="Commitment, 2029">34,000 and $34,000 for cash and in-kind contributions in 2029. Also, in the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company does not believe that the outcome of any claims under indemnification arrangements will have a material effect on its consolidated financial position, results of operations, or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2026 and December 31, 2025. For contingent compensation liability, see the discussion under Footnote 4. Other asset under the NeoRe Project section. Litigation From time to time, the Company may be subject to claims and lawsuits arising in the normal course of business. The Company’s management believes that the outcome of any litigation or claims will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. As of June 30, 2026, management was not aware of any material active, pending, or threatened litigation.

33000

34000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">10.</td> <td>Related Party Activities</td></tr> </table> The Company’s Chilean legal counsel, Quinzio Abogados SpA (“QA”) has power of attorney (“POA”) over and also provide legal counsel to Baltum. Baltum’s contracted general manager is Felipe Quinzio, the sole owner of NyD Mining SpA (“NyD”). Baltum paid NyD for accounting coverage and for the managerial services of Felipe Quinzio during the three and six-months ended June 30, 2026 and June 30, 2025. One of the law partners and owner of QA is Cristian Quinzio, who is the parent of Felipe Quinzio. Baltum pays QA for legal services provided, whether QA is engaged at the request of Baltum or the Company. There were bills for $-0- and $-0- outstanding with Baltum to NyD at June 30, 2026 and June 30, 2025, respectively. There were bills for $6,738 and $-0- outstanding with Baltum to QA at June 30, 2026 and June 30, 2025, respectively. In addition, Baltum accrued an estimate of legal services provided by QA along with VAT due on those services, but yet to be billed by QA in the amount of $31,743 and $3,535 at June 30, 2026 and June 30, 2025, respectively. Baltum incurred legal expenses provided by QA of $37,260 and $12,395 for the three and $43,330 and $26,955 for the six-months ended June 30, 2026 and June 30, 2025, respectively. Baltum incurred managerial and accounting expenses provided by NyD of $10,243 and $10,201 for the three and $20,435 and $20,454 for the six-months ended June 30, 2026 and June 30, 2025, respectively. A Company director, Ash Lazenby, has an advisory agreement with the Company and stands to receive 500,000 RSU’s when they vest in July 2027, which have an intrinsic value of $<span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AshLazenbyMember_zjT9H7hyV5F3" title="Intrinsic value of unvested RSU's">1,095,000 as of June 30, 2026. Also, Mr. Lazenby is a former employee of Glencore Ltd. Glencore Ltd a more than 5% beneficial owner of our capital stock and has a Deed of Undertaking with the Company giving it first and last right of refusal on cobalt and copper off-take from any future production at the Company’s La Cobaltera and El Cofre Projects for the life of the mine. NeoRe SpA is majority-owned by Madesal Mineria SpA, which in turn is majority-owned by Madesal SpA a more than 5% beneficial owner of our capital stock. The Company and NeoRe SpA are parties to a binding Earn-in and Option Agreement that was signed on January 8, 2026, as further described along with the nature of the NeoRe Project business opportunity in Footnote 4. Other assets and Footnote 5. NSR Royalty Asset. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; font-size: 10pt">11.</td> <td style="font-size: 10pt">Subsequent Events</td></tr> </table> Subsequent to June 30, 2026, on August 7, 2026, the Company’s Board of Directors approved the future issuance of an aggregate of 340,000 stock options under the 2025 Plan. These stock options are earmarked for allocation to directors, officers, key independent contractors and advisory board members and are expected to vest over one- and two-year periods, depending on applicable role. As of the date of these financial statements, the official awards have not yet been granted. Consequently, the definitive grant date has not occurred, and the fair value of these options will not be determined until the quarter-end for which the stock options are officially awarded. Therefore, the financial impact of these upcoming awards cannot be reasonably estimated at this time.

1095000

false false false false At the time of determination of expected stock volatility, the Company’s securities were trading over-the-counter as an OTCQB traded stock, but for less than two years and under limited trading volume such that calculated volatility based solely on the Company’s volatility isn’t necessarily indicative of the expected volatility over the expected life of the options and RSUs. Therefore, the expected stock volatility was estimated using three public companies in the same industry as the Company and calculating an equal-weighted and blended volatility of the Company’s volatility and the volatility of those three believed-to-be-representative companies over the same period.